OAM
TNDM icon

Oxford Asset Management’s Tandem Diabetes Care TNDM Stock Holding History

Oxford Asset Management’s Portfolio TNDM Stock Details TNDM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-18,362
Closed -$779K – 2106
2018
Q3 		$779K Buy
+18,362
New +$641K 0.02% 1121

Other funds holding TNDM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Oxford Asset Management's TNDM Position: Q4 2018 in Review

Oxford Asset Management sold out of Tandem Diabetes Care (TNDM) in Q4 2018, closing a stake of 18,362 shares — an estimated $779K sold.

Oxford Asset Management first reported a position in TNDM in Q3 2018 and held it in 1 quarter. The position peaked at $779K in Q3 2018. 200 funds tracked by Wall St. Rank hold TNDM as of Q4 2018.

  • Oxford Asset Management reported no remaining Tandem Diabetes Care position as of Q4 2018 after selling out during the quarter.
  • Oxford Asset Management sold 18,362 Tandem Diabetes Care shares in Q4 2018, an estimated $779K.
  • Oxford Asset Management first reported a position in Tandem Diabetes Care in Q3 2018 and held it in 1 quarter.
  • Oxford Asset Management's Tandem Diabetes Care position peaked at $779K in Q3 2018.
  • 200 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q4 2018.

Based on Oxford Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.